PMD - Psychemedics Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
19.61
-0.17 (-0.86%)
At close: 4:00PM EDT

19.61 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close19.78
Open20.05
Bid19.21 x 1000
Ask20.60 x 1200
Day's Range19.40 - 20.17
52 Week Range15.99 - 27.99
Volume7,484
Avg. Volume7,079
Market Cap107.699M
Beta0.58
PE Ratio (TTM)17.83
EPS (TTM)1.10
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & Yield0.60 (2.82%)
Ex-Dividend Date2018-03-16
1y Target Est32.00
Trade prices are not sourced from all markets
  • Did Psychemedics Corporation (NASDAQ:PMD) Create Value For Shareholders?
    Simply Wall St.5 hours ago

    Did Psychemedics Corporation (NASDAQ:PMD) Create Value For Shareholders?

    The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want a simplistic look at the returnRead More...

  • GlobeNewswirelast month

    James Abely Promoted to VP and General Counsel at Psychemedics Corporation

    Psychemedics Corporation (PMD), the world's largest provider of hair analysis drug testing, today announced that James Abely has been promoted to the position of Vice President and General Counsel. In this important role, Jim is responsible for directing and managing all of the company's legal activities, including working closely with the company's clients, and reports directly to the company's CEO.  Jim joined Psychemedics in June 2016 as Associate General Counsel, after practicing law for 6 years with the Boston firm of Goodwin Procter LLP, following his graduation from the University of Virginia School of Law.  Jim was later promoted to General Counsel.

  • ACCESSWIRE2 months ago

    EX-Dividend Schedule: Psychemedics Boosted its Dividend by 20%; Will Trade Ex-Dividend on May 7, 2018

    LONDON, UK / ACCESSWIRE / May 4, 2018 / Active-Investors has a free review on Psychemedics Corp. (NASDAQ: PMD) following the Company's announcement that it will begin trading ex-dividend on May 07, 2018. Active-Investors has initiated due-diligence on this dividend stock. If your portfolio includes dividend stocks, you have come to the right place for timely information.

  • GlobeNewswire2 months ago

    Psychemedics Corporation Announces New Vice President, Sales and Marketing

    Psychemedics Corporation (PMD) announced the appointment of Charles M. Doucot as the Company's Vice President, Sales and Marketing.  Mr. Doucot will be responsible for global sales and marketing activities and be a key member of the management team, building on the Company's strategic plan. Mr. Doucot brings to Psychemedics Corporation broad experience in sales, strategy and marketing, as well as strong leadership skills.  During a 15-year career at Hewlett Packard Company, Mr. Doucot held numerous sales, strategic alliances, and leadership positions in HP’s first multi-vendor software only sales force with responsibility for both domestic, as well as global programs.  Following HP, Mr. Doucot spent the last 15 years in senior General Management and Business Development roles with Sybase, IDS Scheer, Kalido and Lumesse where he innovated new go to market models focused on new customer acquisition and customer success.

  • Associated Press2 months ago

    Psychemedics: 1Q Earnings Snapshot

    The Acton, Massachusetts-based company said it had profit of 23 cents per share. The drug testing company posted revenue of $10.9 million in the period. Psychemedics shares have climbed slightly more than ...

  • GlobeNewswire2 months ago

    Psychemedics Announces 1Q Record Revenues and Dividend Increase of 20%

    ACTON, Mass., April 24, 2018-- Psychemedics Corporation today announced first quarter financial results for the period ended March 31, 2018. The Company also announced a quarterly dividend of $0.18 per ...

  • ACCESSWIRE3 months ago

    Free Research Report as IQVIA’s Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-Y

    Stock Monitor: Psychemedics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 23, 2018 / Active-Investors.com has just released a free earnings report on IQVIA Holdings Inc. (NYSE: IQV ) ("IQVIA"). ...

  • Only 3 Days Left To Cash In On Psychemedics Corporation (NASDAQ:PMD) Dividend, Is It Worth Buying?
    Simply Wall St.3 months ago

    Only 3 Days Left To Cash In On Psychemedics Corporation (NASDAQ:PMD) Dividend, Is It Worth Buying?

    Attention dividend hunters! Psychemedics Corporation (NASDAQ:PMD) will be distributing its dividend of $0.15 per share on the 29 March 2018, and will start trading ex-dividend in 3 days time onRead More...

  • March Undervalued Utilities Stock Opportunities
    Simply Wall St.3 months ago

    March Undervalued Utilities Stock Opportunities

    Psychemedics and Owens & Minor are utilities stocks on my list that are potentially undervalued. This means their current share prices are trading well-below what the companies are actually worth.Read More...

  • Associated Press4 months ago

    Psychemedics posts 4Q profit

    On a per-share basis, the Acton, Massachusetts-based company said it had net income of 42 cents. Earnings, adjusted for pretax gains, were 22 cents per share. The drug testing company posted revenue of ...

  • 6 Cheap Stocks With a High Dividend Yield
    GuruFocus.com6 months ago

    6 Cheap Stocks With a High Dividend Yield

    Companies with negative stock momentum

  • Capital Cube7 months ago

    ETFs with exposure to Psychemedics Corp. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Psychemedics Corp. Here are 5 ETFs with the largest exposure to PMD-US. Comparing the performance and risk of Psychemedics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Only 3 Days Left Before Psychemedics Corporation (PMD) Will Start Trading Ex-Dividend, Should You Buy?
    Simply Wall St.8 months ago

    Only 3 Days Left Before Psychemedics Corporation (PMD) Will Start Trading Ex-Dividend, Should You Buy?

    Investors who want to cash in on Psychemedics Corporation’s (NASDAQ:PMD) upcoming dividend of $0.15 per share have only 3 days left to buy the shares before its ex-dividend date, 03Read More...

  • Capital Cube8 months ago

    ETFs with exposure to Psychemedics Corp. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Psychemedics Corp. Here are 5 ETFs with the largest exposure to PMD-US. Comparing the performance and risk of Psychemedics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Psychemedics Corp. :PMD-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017
    Capital Cube8 months ago

    Psychemedics Corp. :PMD-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Psychemedics Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Psychemedics Corp. – NeoGenomics, Inc., Enzo Biochem, Inc., Quest Diagnostics Incorporated and Laboratory Corporation of America Holdings (NEO-US, ENZ-US, DGX-US and LH-US) that have also reported for this period. ... Read more (Read more...)

  • PR Newswire8 months ago

    Psychemedics Corporation Announces Q3 Earnings

    DECLARES 85TH CONSECUTIVE QUARTERLY DIVIDEND ACTON, Mass. , Oct. 24, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September ...

  • Does Psychemedics Corporation’s (PMD) PE Ratio Warrant A Buy?
    Simply Wall St.9 months ago

    Does Psychemedics Corporation’s (PMD) PE Ratio Warrant A Buy?

    Psychemedics Corporation (NASDAQ:PMD) trades with a trailing P/E of 13.6x, which is lower than the industry average of 21.5x. While PMD might seem like an attractive stock to buy, itRead More...

  • PR Newswire9 months ago

    Psychemedics Announces Addition of FDA-Cleared Benzodiazepines Hair Test

    ACTON, Mass., Sept. 26, 2017 /PRNewswire/ -- Psychemedics Corporation (PMD), hair testing pioneer and global leader for over thirty years, announced the launch of its FDA-Cleared Benzodiazepines hair test.  The test detects numerous Benzodiazepines, including Xanax®, Valium®, and Ativan®, and is available as a stand-alone test or as an option on Psychemedics' standard drug panels. The abuse of prescription Benzodiazepines has grown at an alarming rate in the United States, contributing to thousands of emergency room visits and overdose deaths each year. It is important to note that Benzodiazepines can prove deadly when combined with other depressants, including alcohol.  This significantly increases the danger of Benzodiazepine abuse.

  • Capital Cube9 months ago

    ETFs with exposure to Psychemedics Corp. : September 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Psychemedics Corp. Here are 5 ETFs with the largest exposure to PMD-US. Comparing the performance and risk of Psychemedics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire10 months ago

    Psychemedics Corporation Launches Synthetic Cannabinoids Hair Test

    ACTON, Mass., Aug. 22, 2017 /PRNewswire/ -- Psychemedics Corporation (PMD), hair testing pioneer and global scientific leader for over thirty years, announced the launch of its Synthetic Cannabinoids test – a hair test that looks for the compounds found in commonly-abused products such as K2, Spice and Blaze. Synthetic Cannabinoids are often marketed as a "legal high" alternative to marijuana, and are commonly sold as incense in retail stores, head shops and on the internet. The Psychemedics test will be continually updated to address changes in the Synthetic Cannabinoids market, adding additional compounds to the test as they are identified or become prevalent as reported by the scientific, law enforcement and regulatory communities.

  • Capital Cube10 months ago

    ETFs with exposure to Psychemedics Corp. : August 21, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Psychemedics Corp. Here are 5 ETFs with the largest exposure to PMD-US. Comparing the performance and risk of Psychemedics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire10 months ago

    Psychemedics Corporation - First Lab Approved For Hair Testing In Iowa

    Psychemedics was instrumental in getting the law changed to include hair, which has a much longer look-back period than other matrices.  Now, less than one month after the law went into effect, the Iowa Department of Public Health has issued a letter approving Psychemedics to conduct private sector pre-employment drug testing using hair.